Intramuscular Drug Delivery Market & Pipeline Insight
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
The research and development of intramuscular drug delivery has gained significant momentum in pharmaceutical industry during past several decades. The high safety and efficacy profiles and familiarity are the most important factor for large investments in this segment. Owing to large past experience and their usage in public programs they have wide acceptance among patients due which their market is expected to be safe for investments. Pharmaceutical companies focused their efforts to churn the market by investing more funds in research and development activities. As a result, newer therapeutics are entering in global market and others are at various phases of clinical trials which are expected to enter in market in near future.
Intramuscular drug delivery market contains therapeutics belonging to different disease indication, mechanism of action and drug delivery devices. The higher sales will depend upon efficacy of newly developed intramuscular drug and marketing strategy to drive its sales. They are used for first-line therapy which they are expected to remain due to their proven pharmacological performance. The large number of patient population is expected to help the pharmaceutical companies in investigating innovative drugs during clinical trials but their market introduction will take some time before gaining success in global market.
Novel technologies are required to develop intramuscular drug delivery including both drug molecule and delivery devices. In addition to these features, new principles have to be found in coming years because most of the presently available intramuscular drug delivery systems are based on old foundations. These factors may work for many disease indications without change for several years but in case of infectious disease, oncology and autoimmune diseases novelty is required. Change in scenario is expected to have multiple effects on drug discovery and development technology along with decreasing the mortality rates. Despite variety in formulations and disease indication, stagnancy will cause severe damage to progress of global intramuscular drug delivery market.
Intramuscular drug delivery methods using molecular structures and polymers are expected to gain momentum in coming years. More structural, physical and biochemical improvements have to take place to increase their marketing potential. Underlying principles behind these materials are being discovered to increase their pharmacological benefits for future usage. Gels are another material required for future development better and efficient delivery of intramuscular drug to the patients. The capabilities of sustained release have been found to be associated with these materials which are expected to make sustainable market place in near future. Researchers are developing new materials with better biodegradability and sustained release capabilities for providing efficient intramuscular drug delivery.
With the recent technological advances, it is expected that newer methods for intramuscular drug delivery will be developed and commercialized in coming years. Market size of these materials and methods is modest which is expected to steady growth but before doing so they have to improve a lot before becoming marketable. Many novel intramuscular drugs are at various phases of clinical trials which are expected to be available after some time. Pharmaceutical companies have already identified the opportunities involved in the development of intramuscular drugs and many of them are at advanced phases of clinical trials. They are supposed to be cost effective along with pharmacologically efficient and minimized side effects.
“Intramuscular Drug Delivery Market & Pipeline Insight” Report Findings:
The research and development of intramuscular drug delivery has gained significant momentum in pharmaceutical industry during past several decades. The high safety and efficacy profiles and familiarity are the most important factor for large investments in this segment. Owing to large past experience and their usage in public programs they have wide acceptance among patients due which their market is expected to be safe for investments. Pharmaceutical companies focused their efforts to churn the market by investing more funds in research and development activities. As a result, newer therapeutics are entering in global market and others are at various phases of clinical trials which are expected to enter in market in near future.
Intramuscular drug delivery market contains therapeutics belonging to different disease indication, mechanism of action and drug delivery devices. The higher sales will depend upon efficacy of newly developed intramuscular drug and marketing strategy to drive its sales. They are used for first-line therapy which they are expected to remain due to their proven pharmacological performance. The large number of patient population is expected to help the pharmaceutical companies in investigating innovative drugs during clinical trials but their market introduction will take some time before gaining success in global market.
Novel technologies are required to develop intramuscular drug delivery including both drug molecule and delivery devices. In addition to these features, new principles have to be found in coming years because most of the presently available intramuscular drug delivery systems are based on old foundations. These factors may work for many disease indications without change for several years but in case of infectious disease, oncology and autoimmune diseases novelty is required. Change in scenario is expected to have multiple effects on drug discovery and development technology along with decreasing the mortality rates. Despite variety in formulations and disease indication, stagnancy will cause severe damage to progress of global intramuscular drug delivery market.
Intramuscular drug delivery methods using molecular structures and polymers are expected to gain momentum in coming years. More structural, physical and biochemical improvements have to take place to increase their marketing potential. Underlying principles behind these materials are being discovered to increase their pharmacological benefits for future usage. Gels are another material required for future development better and efficient delivery of intramuscular drug to the patients. The capabilities of sustained release have been found to be associated with these materials which are expected to make sustainable market place in near future. Researchers are developing new materials with better biodegradability and sustained release capabilities for providing efficient intramuscular drug delivery.
With the recent technological advances, it is expected that newer methods for intramuscular drug delivery will be developed and commercialized in coming years. Market size of these materials and methods is modest which is expected to steady growth but before doing so they have to improve a lot before becoming marketable. Many novel intramuscular drugs are at various phases of clinical trials which are expected to be available after some time. Pharmaceutical companies have already identified the opportunities involved in the development of intramuscular drugs and many of them are at advanced phases of clinical trials. They are supposed to be cost effective along with pharmacologically efficient and minimized side effects.
“Intramuscular Drug Delivery Market & Pipeline Insight” Report Findings:
- Intramuscular Drug Delivery Mechanism
- Global Intramuscular Drug Delivery Market Outlook
- Intramuscular Drug Pipeline by Company, Country, Indication & Phase
- Intramuscular Drug Pipeline: 364 Drugs
- Marketed Intramuscular Drugs: 186 Drugs
- Majority Drugs in Phase-I Trials:108
- Global Intramuscular Drug Delivery Market Future Prospects
1. INTRODUCTION TO INTRAMUSCULAR DRUG DELIVERY
2. OVERVIEW OF DIFFERENT DRUG DELIVERY MECHANISMS
3. INTRAMUSCULAR DRUG DELIVERY MECHANISM
3.1 Mechanism Overview
3.2 Intramuscular Drug Delivery Devices
4. GLOBAL INTRAMUSCULAR DRUG DELIVERY MARKET OUTLOOK
4.1 Market Overview
4.2 Intramuscular Drug Delivery Pipeline Overview
5. GLOBAL INTRAMUSCULAR DRUG DELIVERY MARKET DYNAMICS
5.1 Favorable Market Parameters
5.2 Challenges
6. INTRAMUSCULAR DRUG DELIVERY MARKET FUTURE PROSPECTS
7. INTRAMUSCULAR DRUG PIPELINE BY COMPANY, COUNTRY, INDICATION & PHASE
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-0
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration
7.11 Registered
8. MARKETED INTRAMUSCULAR DRUGS BY COMPANY, COUNTRY & INDICATION
9. DISCONTINUED & SUSPENDED INTRAMUSCULAR DRUGS IN CLINICAL PIPELINE
9.1 No Development Reported
9.2 Discontinued
9.3 Market Withdrawal
9.4 Suspended
10. COMPETITIVE LANDSCAPE
10.1 Antares Pharma
10.2 Eli Lily
10.3 Galaxo
10.4 HMD pharmaceuticals
10.5 Inovio Pharmaceuticals
10.6 Merck
10.7 Novartis
10.8 Pacira Pharmaceuticals
10.9 Pfizer
10.10 Pharmajet
10.11 Teva Pharmaceutical
2. OVERVIEW OF DIFFERENT DRUG DELIVERY MECHANISMS
3. INTRAMUSCULAR DRUG DELIVERY MECHANISM
3.1 Mechanism Overview
3.2 Intramuscular Drug Delivery Devices
4. GLOBAL INTRAMUSCULAR DRUG DELIVERY MARKET OUTLOOK
4.1 Market Overview
4.2 Intramuscular Drug Delivery Pipeline Overview
5. GLOBAL INTRAMUSCULAR DRUG DELIVERY MARKET DYNAMICS
5.1 Favorable Market Parameters
5.2 Challenges
6. INTRAMUSCULAR DRUG DELIVERY MARKET FUTURE PROSPECTS
7. INTRAMUSCULAR DRUG PIPELINE BY COMPANY, COUNTRY, INDICATION & PHASE
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-0
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration
7.11 Registered
8. MARKETED INTRAMUSCULAR DRUGS BY COMPANY, COUNTRY & INDICATION
9. DISCONTINUED & SUSPENDED INTRAMUSCULAR DRUGS IN CLINICAL PIPELINE
9.1 No Development Reported
9.2 Discontinued
9.3 Market Withdrawal
9.4 Suspended
10. COMPETITIVE LANDSCAPE
10.1 Antares Pharma
10.2 Eli Lily
10.3 Galaxo
10.4 HMD pharmaceuticals
10.5 Inovio Pharmaceuticals
10.6 Merck
10.7 Novartis
10.8 Pacira Pharmaceuticals
10.9 Pfizer
10.10 Pharmajet
10.11 Teva Pharmaceutical
LIST OF FIGURES
Figure 1-1: Site of Intramuscular Drug Delivery
Figure 1-2: Various Methods of Drug Delivery
Figure 1-3: Features of Intramuscular Drug Delivery System
Figure 1-4: Classification of Human Muscular System
Figure 1-5: Intramuscular Drug Delivery Sites for Administration
Figure 1-6: Technical Issues with Intramuscular Drug Delivery
Figure 3-1: Factors Affecting Intramuscular Drug Activity
Figure 3-2: Mechanism of Intramuscular Drug Delivery
Figure 3-3: Properties of Intramuscular Drug Delivery
Figure 4-1: Intramuscular Pipeline by Phase (%), 2015
Figure 4-2: Intramuscular Pipeline by Phase (Numbers), 2015
Figure 4-3: No Development Reported Intramuscular Pipeline by Phase (%), 2015
Figure 4-4: No Development Reported Intramuscular Pipeline by Phase (Numbers), 2015
Figure 4-5: Discontinued Intramuscular Pipeline by Phase (%), 2015
Figure 4-6: Discontinued Intramuscular Pipeline by Phase (Numbers), 2015
Figure 4-7: Suspended Intramuscular Pipeline by Phase (%), 2015
Figure 4-8: Suspended Intramuscular Pipeline by Phase (Numbers), 2015
Figure 5-1: Drivers for Intramuscular Drug Delivery Market
Figure 5-2: Challenges for Intramuscular Drug Delivery
Figure 1-1: Site of Intramuscular Drug Delivery
Figure 1-2: Various Methods of Drug Delivery
Figure 1-3: Features of Intramuscular Drug Delivery System
Figure 1-4: Classification of Human Muscular System
Figure 1-5: Intramuscular Drug Delivery Sites for Administration
Figure 1-6: Technical Issues with Intramuscular Drug Delivery
Figure 3-1: Factors Affecting Intramuscular Drug Activity
Figure 3-2: Mechanism of Intramuscular Drug Delivery
Figure 3-3: Properties of Intramuscular Drug Delivery
Figure 4-1: Intramuscular Pipeline by Phase (%), 2015
Figure 4-2: Intramuscular Pipeline by Phase (Numbers), 2015
Figure 4-3: No Development Reported Intramuscular Pipeline by Phase (%), 2015
Figure 4-4: No Development Reported Intramuscular Pipeline by Phase (Numbers), 2015
Figure 4-5: Discontinued Intramuscular Pipeline by Phase (%), 2015
Figure 4-6: Discontinued Intramuscular Pipeline by Phase (Numbers), 2015
Figure 4-7: Suspended Intramuscular Pipeline by Phase (%), 2015
Figure 4-8: Suspended Intramuscular Pipeline by Phase (Numbers), 2015
Figure 5-1: Drivers for Intramuscular Drug Delivery Market
Figure 5-2: Challenges for Intramuscular Drug Delivery
LIST OF TABLES
Table 2-1: Overview of Different Drug Delivery Mechanisms
Table 3-1: Comparative Analysis of Intramuscular Drug Delivery Devices
Table 2-1: Overview of Different Drug Delivery Mechanisms
Table 3-1: Comparative Analysis of Intramuscular Drug Delivery Devices
